Antileishmanial Effect of 1,5- and 1,8-Substituted Fused Naphthyridines
In the absence of a vaccine, there is a need to find new drugs for the treatment of neglected tropical diseases, such as leishmaniasis, that can overcome the many drawbacks of those currently used. These disadvantages include cost, the need to maintain a cold chain, the route of administration, the associated adverse effects and the generation of resistance. In this work we have evaluated the antileishmanial effect of 1,5- and 1,8-substituted fused naphthyridines through in vitro and ex vivo assays, using genetically modified axenic and intramacrophagic Leishmania infantum amastigotes. The toxicity of these compounds has been tested in the mammalian host cell using murine splenic macrophages, as well as in murine intestinal organoids (miniguts) in order to assess their potential for oral administration. The 1,8- derivatives showed greater leishmanicidal activity and the presence of a nitrogen atom in the fused ring to the naphthyridine was important to increase the activity of both types of molecules. The aromatization of the pyridine ring also had marked differences in the activity of the compounds.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Molecules (Basel, Switzerland) - 29(2023), 1 vom: 22. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Melcón-Fernandez, Estela [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiprotozoal Agents |
|---|
| Anmerkungen: |
Date Completed 12.01.2024 Date Revised 12.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/molecules29010074 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366932357 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366932357 | ||
| 003 | DE-627 | ||
| 005 | 20240114234454.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/molecules29010074 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1257.xml |
| 035 | |a (DE-627)NLM366932357 | ||
| 035 | |a (NLM)38202656 | ||
| 035 | |a (PII)74 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Melcón-Fernandez, Estela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antileishmanial Effect of 1,5- and 1,8-Substituted Fused Naphthyridines |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2024 | ||
| 500 | |a Date Revised 12.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In the absence of a vaccine, there is a need to find new drugs for the treatment of neglected tropical diseases, such as leishmaniasis, that can overcome the many drawbacks of those currently used. These disadvantages include cost, the need to maintain a cold chain, the route of administration, the associated adverse effects and the generation of resistance. In this work we have evaluated the antileishmanial effect of 1,5- and 1,8-substituted fused naphthyridines through in vitro and ex vivo assays, using genetically modified axenic and intramacrophagic Leishmania infantum amastigotes. The toxicity of these compounds has been tested in the mammalian host cell using murine splenic macrophages, as well as in murine intestinal organoids (miniguts) in order to assess their potential for oral administration. The 1,8- derivatives showed greater leishmanicidal activity and the presence of a nitrogen atom in the fused ring to the naphthyridine was important to increase the activity of both types of molecules. The aromatization of the pyridine ring also had marked differences in the activity of the compounds | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a fused 1,5-naphthyridines | |
| 650 | 4 | |a fused 1,8-naphthyridines | |
| 650 | 4 | |a intramacrophagic Leishmania parasites | |
| 650 | 4 | |a mouse intestinal organoids | |
| 650 | 4 | |a visceral leishmaniasis | |
| 650 | 7 | |a Antiprotozoal Agents |2 NLM | |
| 650 | 7 | |a Naphthyridines |2 NLM | |
| 700 | 1 | |a Martín-Encinas, Endika |e verfasserin |4 aut | |
| 700 | 1 | |a Palacios, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Galli, Gulio |e verfasserin |4 aut | |
| 700 | 1 | |a Reguera, Rosa M |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Valladares, María |e verfasserin |4 aut | |
| 700 | 1 | |a Balaña-Fouce, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso, Concepción |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Pertejo, Yolanda |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecules (Basel, Switzerland) |d 2004 |g 29(2023), 1 vom: 22. Dez. |w (DE-627)NLM172073448 |x 1420-3049 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:1 |g day:22 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/molecules29010074 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 1 |b 22 |c 12 | ||